Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

NASDAQ:TERN

Overview | Financials
Company Name Terns Pharmaceuticals, Inc.
Symbol TERN
Currency USD
Price 7.23
Market Cap 467,615,426
Dividend Yield 0%
52-week-range 3.26 - 11.819
Industry Biotechnology
Sector Healthcare
CEO Dr. Erin Quirk M.D.
Website https://www.ternspharma.com

An error occurred while fetching data.

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201,

Related Stocks

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.448 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

8.18 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

42.48 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

2.03 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Financials

Numbers are in millions USD

Numbers are in millions USD